Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
People with weight loss resistance are very poor fat burners and have a metabolism that is stuck in sugar burning mode
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
A 26-week diabetes study measured human activity at 1 mg, but its endpoint was blood sugar rather than long-term weight. A short outpatient cohort measured about 4.7% weight loss over four weeks at 2.5 mg. Below 1 mg, estimates rely on pharmacokinetics and mechanism
6f), implying that Gclc deficiency alters mitochondrial metabolism in FoB
Uploading my bloodwork was simple, the doctor consult was quick and efficient, and my medication was at my door within a week
